Tyra Biosciences Inc.

4 days ago · prnewswire.com

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).

8 days ago · prnewswire.com

CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

12 days ago · seekingalpha.com

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

13 days ago · benzinga.com

Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.

13 days ago · investors.com

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.

13 days ago · barrons.com

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

2 months ago · prnewswire.com

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 - CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress.

4 months ago · prnewswire.com

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).

4 months ago · fool.com

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

4 months ago · seekingalpha.com

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript